In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tesaro, Inc.

http://tesarobio.com/

Latest From Tesaro, Inc.

$500m-Plus Pours Into China Bioventures In A Week

From AI-assisted drug discovery to oncotherapy development, China has seen investment pour in over the past week, while the nation's largest online pharmacy is readying for a big Hong Kong debut.

China Financing

'Sakigake' Treatment Gives Enhertu Rapid Japan OK For Gastric Cancer

Japan approves a batch of new products and indications, including Daiichi Sankyo's Enhertu in a high-need indication after a rapid review and Takeda's Zejula, which will be made available to selected patients before its reimbursement listing.

Japan Approvals

GSK Keeps Oncology 2.0 Growth Plans On Track

Oncology R&D head Axel Hoos spoke with Scrip about data at ASCO and the company’s strategy in immuno-oncology, cancer epigenetics, cell and gene therapy and synthetic lethality. 

Cancer Research and Development Strategies

GSK Cancer R&D Chief Sees Three Key Approvals In Q2

GlaxoSmithKline expects regulatory approval for three key cancer products by the middle of this year, anchoring it as a leading oncology company, Axel Hoos tells Scrip.

Approvals Commercial
See All

Company Information

UsernamePublicRestriction

Register